author-photo

Aparna Raychaudhuri

Shire plc

14

Papers

783

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease:

2018 European Journal of Ophthalmology
Show All
- Source
- Cite
- Save
Citations (14)
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3)

2017 Ophthalmology
Show All
- Source
- Cite
- Save
Citations (85)
OP0237 Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: combined evidence from 5 randomized controlled trials

2017 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.

2016 Cornea
Show All
- Source
- Cite
- Save
Citations (54)
Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.

2014 Journal of Clinical Psychopharmacology
Show All
- Source
- Cite
- Save
Citations (8)
Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.

2013 The Journal of Clinical Psychiatry
Show All
- Source
- Cite
- Save
Citations (45)
Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study

2013 BMC Psychiatry
Show All
- Source
- Cite
- Save
Citations (23)
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

2008 Lancet Neurology
Show All
- Source
- Cite
- Save
Citations (401)
A phase I trial of an interleukin‐12/23 monoclonal antibody in relapsing multiple sclerosis

2006 Current Medical Research and Opinion
Show All
- Source
- Cite
- Save
Citations (37)